Passage Bio Inc (PASG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.51+3.24%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PASG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -43.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PASG — private placement
Dated 2026-09-02
Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Remix Therapeutics, Inc., a Delaware corporation (“ Remix ”), entered into an Agreement and Plan of Merger (the “ Original Merger Agreement ”), pursuant to which, among other matters and subject to…
Why it matters: The FDA said PBFT02 needs a randomized trial for registration. The company has cited ethical, practical, and cost hurdles.
Watch forThe company names a workable randomized trial plan for PBFT02 in FTD-GRN. It reports FDA agreement on the design.
Also watch forThe company pauses or ends PBFT02 development. Or it reports that trial design hurdles remain unresolved.
Why it matters: Passage Bio planned to cut its workforce by about 75% by Q3 2026. Completing the cut could reduce costs as the company moves toward a merger.
Supportive ifA company filing or update confirms the planned workforce cut is complete. It reports operating costs below the $8.3 million loss in 2026-Q2.
Worry ifThe company reports that the cut is incomplete, or operating costs rise above the 2026-Q2 level.
Why it matters: The financing is meant to fund the combined company into 2028. A shortfall could limit plans for clinical trials and data releases.
Watch forThe company reports that the $100 million private placement closed before the merger. It also says the proceeds were included in closing cash.
Also watch forThe placement does not close, or reported closing cash excludes much of the planned $100 million.
Why it matters: The merger is set to close in Q4 2026. Passage Bio holders are slated to own about 7% of the combined company.
Watch forPassage Bio stockholders approve the merger, and the company reports that all other closing steps are on track for Q4 2026.
Also watch forStockholders reject the merger. Or the company reports a delay or failure to meet a closing condition.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$198 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $852 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,327 loss on $10,000 · 83.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.